Peripheral T-Cell Lymphoma
Symptoms, Doctors, Treatments, Advances & More

Peripheral T-Cell Lymphoma Overview

Save information for later
Sign Up

Learn About Peripheral T-Cell Lymphoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Peripheral T-Cell Lymphoma Local Doctors?
Elite in Peripheral T-Cell Lymphoma
Hematology | Oncology
Elite in Peripheral T-Cell Lymphoma
Hematology | Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
Experience:
42+ years
Languages Spoken:
English
Offers Telehealth

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 42 years. Dr. Vose is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Peripheral T-Cell Lymphoma
Elite in Peripheral T-Cell Lymphoma

WPHPA Cancer And Blood Specialists Of New York

2 Longview Avenue, 3rd Floor, 
White Plains, NY 
Languages Spoken:
English
Offers Telehealth

Dr. Owen A. O'Connor is internationally renowned for his expertise on the diagnosis and treatment of all forms of lymphoma, with over 25 years of experience in academic medicine. He has invented and pioneered the development of several first in class drugs for the treatment of lymphoma, including one he co-invented for T-cell lymphoma which has now been approved in over 35 countries around the world. He has held several prestigious leadership positions at the major cancer centers in New York City, including Memorial Sloan Kettering Cancer Center, New York University Medical Center, and Cornell and Columbia University Medical Centers. Dr. O'connor is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Anaplastic Large Cell Lymphoma.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Peripheral T-Cell Lymphoma
Anesthesiology
Elite in Peripheral T-Cell Lymphoma
Anesthesiology

Emory University Hospital

1365 Clifton Road Northeast, 
Atlanta, GA 
Experience:
5+ years
Languages Spoken:
English, Spanish
Offers Telehealth

Pamela Allen is an Anesthesiologist practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 5 years. Dr. Allen is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Allen is board certified in American Board Of Anesthesiology, 2025.

What are the latest Peripheral T-Cell Lymphoma Clinical Trials?
Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

Summary: This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The graft is the donor blood cells that patients get during the transplant. The host is the person receiving...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Summary: Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).